See more : Thruvision Group plc (THRU.L) Income Statement Analysis – Financial Results
Complete financial analysis of Asymchem Laboratories (Tianjin) Co., Ltd. (002821.SZ) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Asymchem Laboratories (Tianjin) Co., Ltd., a leading company in the Biotechnology industry within the Healthcare sector.
- Vishnu Prakash R Punglia Limited (VPRPL.NS) Income Statement Analysis – Financial Results
- Kirloskar Brothers Limited (KIRLOSBROS.BO) Income Statement Analysis – Financial Results
- Doxa AB (publ) (DOXA.ST) Income Statement Analysis – Financial Results
- Ivy Cosmetics Corporation (4918.T) Income Statement Analysis – Financial Results
- BlackRock Greater Europe Investment Trust plc (BRGE.L) Income Statement Analysis – Financial Results
Asymchem Laboratories (Tianjin) Co., Ltd. (002821.SZ)
About Asymchem Laboratories (Tianjin) Co., Ltd.
Asymchem Laboratories (Tianjin) Co., Ltd. provides contract development and manufacturing organization services in Mainland China and internationally. The company offers drug research and development, and manufacturing services for pharmaceutical and biotech companies. Its solutions range from early clinical stage to commercial stage, including research and development, and cGMP production of advanced intermediates, active pharmaceutical ingredients, and formulations, as well as clinical research services. The company also engages in the provision of pharmaceutical analysis and testing services; sale, wholesale, and retail of drugs; and pharmaceutical science and technology development activities. The company was founded in 1999 and is headquartered in Tianjin, China.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 7.83B | 10.26B | 4.64B | 3.15B | 2.46B | 1.83B | 1.42B | 1.10B | 830.61M | 716.21M | 542.76M | 424.40M | 405.69M |
| Cost of Revenue | 3.83B | 5.40B | 2.58B | 1.68B | 1.34B | 981.67M | 686.73M | 533.92M | 430.09M | 404.45M | 299.53M | 228.24M | 217.20M |
| Gross Profit | 3.99B | 4.86B | 2.06B | 1.47B | 1.12B | 853.20M | 736.30M | 569.28M | 400.52M | 311.76M | 243.23M | 196.16M | 188.49M |
| Gross Profit Ratio | 51.02% | 47.37% | 44.33% | 46.55% | 45.50% | 46.50% | 51.74% | 51.60% | 48.22% | 43.53% | 44.81% | 46.22% | 46.46% |
| Research & Development | 707.86M | 708.89M | 387.48M | 258.93M | 192.52M | 155.18M | 97.24M | 70.48M | 65.10M | 52.74M | 44.24M | 40.13M | 0.00 |
| General & Administrative | 293.92M | 235.44M | 153.29M | 80.05M | 77.10M | 63.82M | 55.82M | 34.21M | 24.22M | 22.04M | 16.41M | 95.43M | 76.19M |
| Selling & Marketing | 64.29M | 150.19M | 99.56M | 84.25M | 87.53M | 74.37M | 53.53M | 43.05M | 36.59M | 31.01M | 26.40M | 24.91M | 25.58M |
| SG&A | 358.21M | 385.63M | 252.85M | 164.30M | 164.63M | 138.19M | 109.35M | 77.26M | 60.81M | 53.04M | 42.81M | 120.34M | 101.76M |
| Other Expenses | 366.53M | 591.09M | 240.42M | 151.95M | 119.83M | -765.10K | 2.49M | 10.62M | -905.66K | 11.39M | 13.93M | 14.66M | 12.40M |
| Operating Expenses | 1.42B | 1.69B | 880.75M | 575.19M | 476.99M | 401.11M | 252.53M | 271.73M | 220.65M | 182.01M | 144.98M | 122.25M | 104.17M |
| Cost & Expenses | 5.25B | 7.08B | 3.46B | 2.26B | 1.82B | 1.38B | 939.27M | 805.65M | 650.74M | 586.46M | 444.51M | 350.49M | 321.37M |
| Interest Income | 160.14M | 76.62M | 12.99M | 15.11M | 4.96M | 3.81M | 7.98M | 621.20K | 1.49M | 1.48M | 833.72K | 0.00 | 0.00 |
| Interest Expense | 6.32M | 10.53M | 7.33M | 2.50M | 773.26K | 1.36M | 1.39M | 6.55M | 1.98M | 3.44M | 4.47M | 2.73M | 4.76M |
| Depreciation & Amortization | 486.86M | 361.98M | 216.75M | 159.88M | 124.95M | 103.98M | 75.19M | 62.72M | 53.12M | 47.76M | 40.35M | 30.10M | 20.81M |
| EBITDA | 3.05B | 4.07B | 1.42B | 973.69M | 746.59M | 568.09M | 498.62M | 398.11M | 254.80M | 183.81M | 145.62M | 104.01M | 105.13M |
| EBITDA Ratio | 39.01% | 39.32% | 30.95% | 31.56% | 31.24% | 30.50% | 35.90% | 36.09% | 30.61% | 26.43% | 27.00% | 24.99% | 26.51% |
| Operating Income | 2.57B | 3.73B | 1.19B | 816.89M | 623.67M | 461.39M | 419.59M | 314.92M | 200.46M | 121.24M | 86.96M | 69.17M | 77.18M |
| Operating Income Ratio | 32.85% | 36.38% | 25.70% | 25.94% | 25.35% | 25.15% | 29.49% | 28.55% | 24.13% | 16.93% | 16.02% | 16.30% | 19.02% |
| Total Other Income/Expenses | -13.66M | -5.84M | 587.45K | -2.14M | -80.98K | -765.10K | 2.49M | 10.55M | -905.69K | 11.26M | 13.84M | 9.90M | 12.38M |
| Income Before Tax | 2.56B | 3.72B | 1.19B | 814.36M | 623.59M | 460.62M | 422.08M | 325.47M | 199.55M | 132.50M | 100.80M | 83.81M | 89.56M |
| Income Before Tax Ratio | 32.68% | 36.32% | 25.72% | 25.86% | 25.35% | 25.10% | 29.66% | 29.50% | 24.03% | 18.50% | 18.57% | 19.75% | 22.08% |
| Income Tax Expense | 306.31M | 430.31M | 123.69M | 92.30M | 69.72M | 54.17M | 62.03M | 49.86M | 29.84M | 18.80M | 16.03M | 12.42M | 13.77M |
| Net Income | 2.27B | 3.30B | 1.07B | 722.09M | 553.86M | 428.30M | 341.29M | 252.74M | 153.55M | 101.79M | 74.73M | 60.25M | 65.37M |
| Net Income Ratio | 28.99% | 32.19% | 23.05% | 22.93% | 22.51% | 23.34% | 23.98% | 22.91% | 18.49% | 14.21% | 13.77% | 14.20% | 16.11% |
| EPS | 6.26 | 9.02 | 3.15 | 2.21 | 1.73 | 1.34 | 1.08 | 0.99 | 0.61 | 0.40 | 0.30 | 0.24 | 0.26 |
| EPS Diluted | 6.26 | 9.00 | 3.13 | 2.20 | 1.71 | 1.33 | 1.06 | 0.99 | 0.61 | 0.40 | 0.30 | 0.24 | 0.26 |
| Weighted Avg Shares Out | 362.43M | 366.03M | 339.64M | 326.11M | 320.42M | 318.94M | 316.43M | 256.40M | 251.42M | 252.21M | 252.10M | 251.78M | 250.74M |
| Weighted Avg Shares Out (Dil) | 362.43M | 366.85M | 341.34M | 328.22M | 323.09M | 322.37M | 320.67M | 256.40M | 251.42M | 252.23M | 252.10M | 251.80M | 250.74M |
Source: https://incomestatements.info
Category: Stock Reports